Black Diamond Therapeutics, Inc. (BDTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.93

From 52W high−59.75%

Volume1.17M

Market cap$112.61M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.93

From 52W high

−59.75%

Volume

1.17M

Market cap

$112.61M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

P/E (TTM)

—

RSI (14)

40.7

MomentumView details →

1D Return

+1.55%

YTD Return

−21.19%

SummaryUpdated Jun 1, 2026

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a clinical-stage biotechnology company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as ASET Therapeutics, the company rebranded to Black Diamond Therapeutics in January 2018 and went public in January 2020. The company focuses on discovering, developing, and commercializing precision medicines for patients with genetically defined tumors, particularly targeting specific mutations in cancer-driving proteins.

Ask drillr about Black Diamond Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−44.29%

ROA (TTM)

−34.04%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+130.71%

EBITDA YoY

—

MomentumView details →

1D Return

+1.55%

YTD Return

−21.19%

1Y Return

−41.62%

RSI (14)

40.7

vs 50D SMA

−2.67%

vs 200D SMA

−17.24%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

7.28x

Quick Ratio

7.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.17

EPS Surprise

13.02%

Beats (12Q)

11/12

Next Q EPS Est

−$0.09

Avg Surprise (4Q)

19.42%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−42.55M

Op. CF (TTM)

−32.01M

Next earningsNov 5, 2026 →

Latest newsMore news →

Black Diamond Therapeutics reported Q2 2026 financial results with a net loss of $9.9 million and cash and investments of $110.5 million as of June 30, 2026.47d ago

Similar companies

PMV Pharmaceuticals, Inc.PMVP Vaxart, Inc.VXRT Milestone Pharmaceuticals Inc.MIST Genelux CorporationGNLX Coya Therapeutics, Inc.COYA Cyclerion Therapeutics, Inc.CYCN Find similar companies →

Latest newsMore news →

Black Diamond Therapeutics reported Q2 2026 financial results with a net loss of $9.9 million and cash and investments of $110.5 million as of June 30, 2026.47d ago